http://venturebeat.disqus.com/News about Tech, Business and InnovationenThu, 31 Jan 2008 08:15:54 -0000http://venturebeat.com/2008/01/28/rna-drug-developer-quark-aims-for-30m-following-failed-ipo/#comment-14682378<p>Technically, the licenses with Silence (and also Alnylam) are really to gain FTO to use siRNAs therapeutically for several gene targets of interest. Quark probably knew they wanted to target these proteins (p53 and RTP801) through their discovery platform and/or collaborations they had in place.</p><p>Zucker probably objected to the term new-comer to differentiate themselves from the "really" new players, e.g. Dicerna</p>EricThu, 31 Jan 2008 08:15:54 -0000